Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
ORGANIZATION
Fast-Track Approval System, New Pricing Rules Needed for Therapeutic Apps: DTx Consortium
The Japan Digital Therapeutics Consortium, which is made up of seven companies including drug makers developing therapeutic apps, is calling for the introduction of a fast-track approval system and new pricing rules for such products. Rie Fukaya, global clinical regulatory…
To read the full story
Related Article
- Japan’s 1st Therapeutic App Now Available: CureApp
December 2, 2020
- Keidanren Calls for Clearer Classification Criteria for “Software as a Medical Device” to Promote Development
October 21, 2020
- Mitsubishi Tanabe to Develop Mobile App for Depression Treatment
September 3, 2020
- Astellas Links Up with US Health Tech Welldoc in Digital Therapeutics
November 22, 2019
- Shionogi Bags Japan/Taiwan Rights to Akili’s Digital Medicines for ADHD, Autism
March 8, 2019
ORGANIZATION
- EFPIA Urges Global-Level Launch Prices, Patent-Term Price Protection
June 26, 2026
- Industry Hails Japan Growth Roadmap, PhRMA Urges Follow-Through
June 25, 2026
- Boehringer’s Hasson Appointed EFPIA Japan Vice Chair
June 22, 2026
- Think Tank Opposes Cap on Social Security Burden Ratio, Urges Pause in Off-Year Price Cuts
June 22, 2026
- Japanese Drug Makers Step Up Use of ASEAN Reliance Reviews
June 18, 2026
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…